阿仑膦酸钠对绝经后骨质疏松症患者骨密度及血清碱性磷酸酶、骨钙素的影响

Effect of alendronate sodium on serum alkaline phosphatase,osteocalcin and bone mineral density in patients with postmenopausal osteoporosis

目的:探讨阿仑膦酸钠对绝经后骨质疏松症患者骨密度(BMD)及血清碱性磷酸酶(ALP)、骨钙素(BGP)的影响。方法:62例绝经后骨质疏松症患者随机分为2组,治疗组32例,对照组30例。治疗组口服阿仑膦酸钠、阿法迪三;对照组口服阿法迪三。分别于治疗前、治疗6个月、治疗12个月双能X线骨密度仪测定患者正位腰椎(L 2～4)、髋部股骨颈(Neck)、大转子(Troch)和Ward’s三角区BMD,全自动生物分析仪测定血清ALP和BGP含量。结果:治疗组治疗6个月、12个月血清ALP和BGP含量与对照组比较有明显差异(P<0.01)。治疗组,治疗12个月后L1-4和髋部(Neck,Troch,Ward’s)BMD值与治疗前比较显著增加(P<0.01)。治疗组与对照组比较L1-4和全髋部BMD值明显差异(P<0.01)。结论:阿仑膦酸钠能有效阻止绝经后骨矿丢失,降低血清ALP含量和提高血清BGP含量。

Objective：To investigate the effect of alendronate sodium on serum alkaline phosphatase （ALP）, osteocalcin and bone mineral density （BMD） in patients with postmenopausal osteoporosis. Methods： A total of 62 postmenopausal women with osteoporosis were randomly divided into 2 groups： 32 treatment patients received alen- dronate sodium and Alpha D3 treatment, and 30 control patients received Alpha D3 only. Before treatment, 6 and 12 months after treatment, the postmenopausal BMD of anterior - posterior lumbar spines and proximal femur were determined by dual -energy X -ray absorptiometry, and the serum alkaline phosphatase and osteocalcin were detected. Results： Compared with control group, the serum ALP and osteoealcin levels were significantly decreased 6 and 12 months after treatment （P 〈 0.01 ）. Compared with that before treatment, the BMD value of the lumbar spine and proximal femur was significantly increased 12 months after treatment （P 〈 0.05 ）. There was also obvious difference in BMD level of the lumbar spine and proximal femur 12 months after treatment between treatment group and control group （P 〈 0.05 ）. Conclusion： Alendronate sodium is effective for the patients with postmenopausal osteoporosis, which can decrease the serum ALP level and increase the serum osteocalcin level.